Prognostic significance of blood transfusion and anaemia on survival in stage IIIA/B/C and IVA oesophageal cancers treated with chemoradiotherapy
- First Online:
- 178 Downloads
To evaluate the prognostic effect of blood transfusion (BT) on survival outcomes in patients with stage IIIA/B/C and IVA oesophageal cancers treated with induction chemotherapy and chemoradiotherapy (C → CRT).
The medical records of patients with oesophageal cancer treated with C → CRT at the Royal Marsden Hospital, U.K. between 2000 and 2007 were identified and reviewed retrospectively. Patients had weekly haemoglobin measurements and received BT to maintain haemoglobin at the level of 12 g/dL and above as per the institutional policy. Overall survival (OS), progression-free survival (PFS) and locoregional recurrence-free survival (LRFS) were estimated by the Kaplan-Meier method. Cox proportional hazards regression models were used to determine the effect of anaemic and transfusion status on survival outcomes after adjusting for selected prognostic characteristics.
Among 151 stage IIIA/B/C and IVA patients, the two-year rates for OS (53 and 53 vs. 27 %), PFS (36 and 29 vs. 22 %) and LRFS (57 and 59 vs. 43 %) were higher in those who were not anaemic and those who were anaemic with transfusion vs. those who were anaemic without transfusion, respectively. At multivariate analysis, anaemic patients who received blood transfusion had significantly lower risk of death (hazard ratios (HR) = 0.41, 95 % CI 0.23–0.74, p = 0.003), progression (HR = 0.46, 95 % CI 0.25–0.84, p = 0.009) and locoregional relapse (HR = 0.38, 95 % CI 0.16–0.89, p = 0.025) vs. those who did not.
With these current data, there was a significant benefit of BT in stage IIIA/B/C and IVA oesophageal cancers treated with chemoradiation.
KeywordsBlood transfusion Anaemia Hypoxia Oesophageal cancer Chemoradiation
- 1.UK CR. Cancer incidence-UK statistics. In Edition 2012Google Scholar
- 2.Statistics OfN. Cancer statistics registrations: registrations of cancer diagnosed in 2007, England. In National Statistics, Edition no.38. London.: 2012Google Scholar
- 3.Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006; CD002092Google Scholar
- 15.Yi Y, Li B, Sun H et al. Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Tumour Biol 31: 333–340Google Scholar
- 24.DeMaeyer EM. Preventing and controlling iron deficiency anaemia through primary health care : a guide for health administrators and programme managers. World Health Organization 1989Google Scholar
- 26.Molls M, Vaupel P, Brown JM (1998) Blood perfusion and microenvironment of human tumors: implications for clinical radiooncology. Springer, LondonGoogle Scholar
- 32.NCCN. Cancer- and chemotherapy-induced anaemia. In NCCN Clinical Practice Guidelines in Oncology, Edition 2010Google Scholar
- 35.Overgaard J, Hansen HS, Overgaard M et al (1998) A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5–85. Radiother Oncol 46:135–146PubMedCrossRefGoogle Scholar
- 36.Girinski T, Pejovic-Lenfant MH, Bourhis J et al (1989) Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 16:37–42PubMedCrossRefGoogle Scholar
- 39.Hoff CM, Grau C, Overgaard J. Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma—a prospective study. Radiother Oncol 103: 38–44Google Scholar
- 41.Zhao KL, Liu G, Jiang GL et al (2006) Association of haemoglobin level with morbidity and mortality of patients with locally advanced oesophageal carcinoma undergoing radiotherapy—a secondary analysis of three consecutive clinical phase III trials. Clin Oncol (R Coll Radiol) 18:621–627CrossRefGoogle Scholar